Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

前列腺癌 医学 前列腺癌的治疗 投票 德尔菲法 前列腺 协商一致会议 癌症 疾病 肿瘤科 妇科 内科学 法学 统计 政治 数学 政治学
作者
Silke Gillessen,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Anders Bjartell,Alberto Bossi,Alberto Briganti,Robert G. Bristow,Kim N.,Noel W. Clarke,Ian D. Davis,Johann S. de Bono,Charles G. Drake,Ignacio Durán,Ros Eeles,Eleni Efstathiou,Christopher P. Evans,Stefano Fanti,Felix Y. Feng,Karim Fizazi,Mark Frydenberg,Martin Gleave,Susan Halabi,Axel Heidenreich,Daniel Heinrich,Celestia S. Higano,Michael S. Hofman,Maha Hussain,Nicholas D. James,Ravindran Kanesvaran,Philip W. Kantoff,Raja B. Khauli,Raya Leibowitz,C. Logothetis,Fernando C. Maluf,Robin Millman,Alicia K. Morgans,Michael J. Morris,Nicolas Mottet,Hind Mrabti,Declan G. Murphy,Vedang Murthy,William Oh,Piet Ost,Joe M. O’Sullivan,Anwar R. Padhani,Chris Parker,Darren M. C. Poon,Colin C. Pritchard,Robert E. Reiter,Mack Roach,Mark A. Rubin,Charles J. Ryan,Fred Saad,Juan Pablo Sade,Oliver Sartor,Howard I. Scher,Neal D. Shore,Eric J. Small,Matthew R. Smith,Howard R. Soule,Cora N. Sternberg,Thomas Steuber,Hiroyoshi Suzuki,Christopher J. Sweeney,Matthew R. Sydes,Mary-Ellen Taplin,Bertrand Tombal,Levent Türkeri,Inge M. van Oort,A. Zapatero,Aurelius Omlin
出处
期刊:European Urology [Elsevier BV]
卷期号:77 (4): 508-547 被引量:276
标识
DOI:10.1016/j.eururo.2020.01.012
摘要

Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some of these topics to supplement guidelines that are based on level 1 evidence. To present the results from the APCCC 2019. Similar to prior conferences, experts identified 10 important areas of controversy regarding the management of advanced prostate cancer: locally advanced disease, biochemical recurrence after local therapy, treating the primary tumour in the metastatic setting, metastatic hormone-sensitive/naïve prostate cancer, nonmetastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, bone health and bone metastases, molecular characterisation of tissue and blood, inter- and intrapatient heterogeneity, and adverse effects of hormonal therapy and their management. A panel of 72 international prostate cancer experts developed the programme and the consensus questions. The panel voted publicly but anonymously on 123 predefined questions, which were developed by both voting and nonvoting panel members prior to the conference following a modified Delphi process. Panellists voted based on their opinions rather than a standard literature review or formal meta-analysis. The answer options for the consensus questions had varying degrees of support by the panel, as reflected in this article and the detailed voting results reported in the Supplementary material. These voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse. However, diagnostic and treatment decisions should always be individualised based on patient-specific factors, such as disease extent and location, prior lines of therapy, comorbidities, and treatment preferences, together with current and emerging clinical evidence and logistic and economic constraints. Clinical trial enrolment for men with advanced prostate cancer should be strongly encouraged. Importantly, APCCC 2019 once again identified important questions that merit assessment in specifically designed trials. The Advanced Prostate Cancer Consensus Conference provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference, which has been held three times since 2015, aims to share the knowledge of world experts in prostate cancer management with health care providers worldwide. At the end of the conference, an expert panel discusses and votes on predefined consensus questions that target the most clinically relevant areas of advanced prostate cancer treatment. The results of the voting provide a practical guide to help clinicians discuss therapeutic options with patients as part of shared and multidisciplinary decision making.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小蜜蜂完成签到,获得积分10
刚刚
在水一方的应助被喝口可乐采纳,获得30
刚刚
LW3366发布了新的文献求助10
1秒前
马亚斌发布了新的文献求助10
1秒前
秋风的应助被芒果彩虹猪采纳,获得20
2秒前
GPTea的应助被jean采纳,获得20
2秒前
applennad完成签到,获得积分10
2秒前
3秒前
4秒前
4秒前
努力搬砖的小胡完成签到,获得积分10
5秒前
稳重的元瑶完成签到,获得积分10
5秒前
马亚斌完成签到,获得积分20
6秒前
瓦松完成签到,获得积分20
7秒前
等风归完成签到,获得积分10
7秒前
云朝完成签到,获得积分10
8秒前
9秒前
9秒前
ZeKaWa的应助被liu采纳,获得10
9秒前
PEACE完成签到 ,获得积分20
9秒前
儒雅黑猫完成签到 ,获得积分10
9秒前
10秒前
思恩Shen发布了新的文献求助10
10秒前
秦风完成签到,获得积分10
11秒前
杜欣悦发布了新的文献求助10
11秒前
香蕉觅云的应助被顺利毕业mpa采纳,获得10
11秒前
94完成签到,获得积分10
11秒前
fighting完成签到,获得积分10
12秒前
13秒前
13秒前
哈47发布了新的文献求助10
14秒前
俭朴含卉完成签到 ,获得积分10
14秒前
饼饼完成签到,获得积分20
14秒前
虚幻明杰完成签到,获得积分10
14秒前
Johnny发布了新的文献求助10
15秒前
wxz1998完成签到,获得积分10
15秒前
O基米德发布了新的文献求助10
15秒前
16秒前
田様的应助被木头采纳,获得10
16秒前
吱哦周完成签到,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621